InsiderTrades.com logo
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

CTCX Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $65,744.43
Insider Selling (Last 12 Months): $0.00

Carmell Insider Trading History Chart

This chart shows the insider buying and selling history at Carmell by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Carmell Share Price & Price History

Current Price: $2.86
Price Change: ▼ Price Decrease of -0.07 (-2.39%)
As of 11/28/2023 01:00 AM ET

This chart shows the closing price history over time for CTCX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
An Unusual Way to Invest in Gold
From Edge On The Street   |   Ad
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
See why this overlooked gold play

Carmell Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2023Rajiv ShuklaCEOBuy2,100$2.97$6,237.0020,562View SEC Filing Icon  
11/24/2023Rajiv ShuklaCEOBuy2,715$2.95$8,009.2518,462View SEC Filing Icon  
11/22/2023Rajiv ShuklaCEOBuy1,185$2.78$3,294.3015,747View SEC Filing Icon  
11/20/2023Rajiv ShuklaCEOBuy3,750$2.62$9,825.0014,362View SEC Filing Icon  
11/17/2023Rajiv ShuklaCEOBuy2,000$2.69$5,380.0010,612View SEC Filing Icon  
8/28/2023Rajiv ShuklaChairmanBuy2,100$3.50$7,350.008,612View SEC Filing Icon  
8/28/2023Randolph W HubbellCEOBuy100$3.49$349.002,750View SEC Filing Icon  
8/25/2023Randolph W HubbellCEOBuy200$3.50$700.002,650View SEC Filing Icon  
8/24/2023Rajiv ShuklaChairmanBuy500$3.50$1,750.005,912View SEC Filing Icon  
8/23/2023Randolph W HubbellCEOBuy200$3.60$720.002,250View SEC Filing Icon  
8/21/2023Rajiv ShuklaChairmanBuy100$3.54$354.005,412View SEC Filing Icon  
8/21/2023Randolph W HubbellCEOBuy300$3.67$1,101.001,950View SEC Filing Icon  
8/18/2023Rajiv ShuklaChairmanBuy4,100$3.62$14,842.005,312View SEC Filing Icon  
8/17/2023Randolph W HubbellCEOBuy450$3.72$1,674.00450View SEC Filing Icon  
8/16/2023Rajiv ShuklaChairmanBuy1,112$3.74$4,158.881,112View SEC Filing Icon  
See Full Table
An Unusual Way to Invest in Gold
From Edge On The Street   |   Ad
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
See why this overlooked gold play

SEC Filings (Institutional Ownership Changes) for Carmell (NASDAQ:CTCX)

67.16% of Carmell stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Carmell Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2023Linden Advisors LP75,000$0.27M0.0%N/A0.390%Search for SEC Filing on Google Icon
11/14/2023Meteora Capital LLC1,780,919$6.42M1.1%N/A9.256%Search for SEC Filing on Google Icon
11/7/2023Cookson Peirce & Co. Inc.15,000$54K0.0%N/A0.078%Search for SEC Filing on Google Icon
11/1/2023Carnegie Mellon University103,061$0.37M0.5%N/A0.536%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Carmell logo
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Read More on Carmell

Today's Range

Now: $2.86
Low: $2.85
High: $2.95

50 Day Range

MA: $2.86
Low: $1.85
High: $4.78

52 Week Range

Now: $2.86
Low: $1.70
High: $13.31

Volume

10,551 shs

Average Volume

204,882 shs

Market Capitalization

$55.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Carmell?

Carmell's top insider shareholders include:
  1. Rajiv Shukla (CEO)
  2. Rajiv Shukla (Chairman)
  3. Randolph W Hubbell (CEO)
Learn More about top insider investors at Carmell.

Who are the major institutional investors of Carmell?

Carmell's top institutional investors include:
  1. Meteora Capital LLC — 9.26%
  2. Carnegie Mellon University — 0.54%
  3. Linden Advisors LP — 0.39%
  4. Cookson Peirce & Co. Inc. — 0.08%
Learn More about top institutional investors of Carmell stock.

Which major investors are buying Carmell stock?

During the previous quarter, CTCX stock was bought by institutional investors including:
  1. Meteora Capital LLC
  2. Carnegie Mellon University
  3. Linden Advisors LP
  4. Cookson Peirce & Co. Inc.
Within the last year, these company insiders have bought Carmell stock:
  1. Rajiv Shukla (CEO)
  2. Rajiv Shukla (Chairman)
  3. Randolph W Hubbell (CEO)
Learn More investors buying Carmell stock.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.